Get started
Author

Károly Szepesházi

Observed names: K Szepeshazi, K Szepesházi, K. Szepeshazi, K. Szepesházi, KAROLY SZEPESHAZI, Karoly SZEPESHAZI, Karoly Szepeshazi, Karoly Szepesházi, Szepesházi, Károly
Observed institutions: Semmelweis University, Tulane University, United States Department of Veterans Affairs, University of Miami, Veterans Health Administration, National Institute of Oncology, Southeast Louisiana Veterans Health Care System, South Florida Veterans Affairs Foundation for Research and Education, Miami VA Healthcare System
OpenAlex ID: A5110414161
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
1996 · A Nagy, A V Schally, et al. · Proceedings of the National Academy of Sciences · 204
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
1998 · Attila Nagy, Andrew V. Schally, et al. · Proceedings of the National Academy of Sciences · 145
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues
2005 · Alexandre Havt, Andrew V. Schally, et al. · Proceedings of the National Academy of Sciences · 119
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
1997 · A. Jungwirth, J. Pinski, et al. · European Journal of Cancer · 97
Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing Hormone
1995 · J. Pinski, A. V. Schally, et al. · JNCI Journal of the National Cancer Institute · 91
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
1997 · Attila Nagy, Patricia Armatis, et al. · Proceedings of the National Academy of Sciences · 88
The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas
2002 · Rebeca Busto, Andrew V. Schally, et al. · Proceedings of the National Academy of Sciences · 85
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
1994 · T Yano, J Pinski, et al. · Proceedings of the National Academy of Sciences · 79
Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice
1993 · Jacek Pinski, Andrew V. Schally, et al. · International Journal of Cancer · 79
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia
2011 · Ferenc G. Rick, Andrew V. Schally, et al. · Proceedings of the National Academy of Sciences · 78
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases
2012 · Ferenc G. Rick, Andrew V. Schally, et al. · Proceedings of the National Academy of Sciences · 77
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
1999 · A Plonowski, A V Schally, et al. · PubMed · 76
Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160
1994 · Jucek Pinski, Gabor Halmos, et al. · International Journal of Cancer · 74
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
1991 · K Szepeshazi, A V Schally, et al. · PubMed · 72
Growth Inhibition of Human Ovarian Cancers by Cytotoxic Analogues of Luteinizing Hormone-Releasing Hormone
1997 · M. Miyazaki, A. Nagy, et al. · JNCI Journal of the National Cancer Institute · 70
True
2000 · K Szepeshazi, A V Schally, et al. · British Journal of Cancer · 68
PDF
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs
2004 · A. V. Schally, K. Szepeshazi, et al. · Cellular and Molecular Life Sciences · 67
Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
1992 · T W Redding, A V Schally, et al. · PubMed · 65
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095
1998 · M Miyazaki, N Lamharzi, et al. · European Journal of Cancer · 63
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours
2000 · K. Szepeshazi, A.V. Schally, et al. · European Journal of Cancer · 61
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
1997 · Andreas Jungwirth, Georg Galvan, et al. · The Prostate · 60
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
2003 · Zoltan Szereday, Andrew V Schally, et al. · PubMed · 58
Growth Inhibition of Estrogen-Dependent and Estrogen-Independent MXT Mammary Cancers in Mice by the Bombesin and Gastrin-Releasing Peptide Antagonist RC-3095
1992 · Karoly Szepeshazi, Andrew V. Schally, et al. · JNCI Journal of the National Cancer Institute · 57
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
1994 · J Pinski, A V Schally, et al. · PubMed · 55
Targeted cytotoxic analogue of bombesin/ gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice
1999 · H Kiaris, A V Schally, et al. · British Journal of Cancer · 53
PDF
Works count: 129
Citation count: 3,955
H-index: 41
I10-index: 85
Year
Topic
Type